Tier C

NMNH (Reduced β-NMN · Reduced Nicotinamide Mononucleotide)

Also known as: Reduced NMN · β-NMNH · Dihydro-NMN

1 PMID anchor · MITO · METABOLISM · Last reviewed 2026-06-02

Read full dossier → Deep-dive article → JSON (nmnh.json)

Mechanism of action

Direct NADH pool elevation (preclinical mouse)
Mitochondrial absorption hypothetical
NMNAT-independent NAD+ enhancement (Liu 2021 preclinical)

Molecular + tissue targets

NAD+ pool (reduced form)
NMNAT enzymes (preclinical)
Mitochondria

Dosage range

No established human dosing · supplement market 100-300 mg/day (unsupported · Liu 2021 PMID 33793246 mouse 13.6 mg/kg IP only)

Safety notes

NO human RCT · Liu 2021 PMID 33793246 mouse 4-week IP 13.6 mg/kg/day · "better than NMN" marketing framing premature · cell-cycle arrest + glycolysis suppression observed in vitro (mechanism caution)

Cross-market regulatory status

🇺🇸 FDA

NOT GRAS · no NDIN filed · status pending

🇪🇺 EFSA

Novel Food required · no authorization

🇧🇷 ANVISA

IN 28/2018 GE registration required · no specific framework

Common use cases

NAD+ enhancement (preclinical mouse · 0 human RCT)
experimental NAD+ precursor

Cross-reference

Health goals: longevity stack

Full dossier: /ingredients/nmnh/

Machine-readable JSON: /api/nc/nmnh.json